Company Overview and News
AWC Bhd (Oct 15, 80.5 sen) Maintain add with a target price (TP) of RM1.26: A one-day non-deal roadshow was hosted in Singapore on Oct 5, 2018 for AWC Bhd’s management to meet institutional investors. The company met six fund managers. AWC was represented by its chief financial officer Richard Voon and vice-president Hisham Najmuddeen, who was in charge of special projects and investments.
UEM Edgenta Bhd (Oct 5, RM2.70) Initiate coverage with buy and a target price (TP) of RM3.22: UEM Edgenta Bhd is Malaysia’s largest integrated facilities management (IFM) provider. Its expertise covers consultancy, services and solutions for the healthcare, infrastructure and real estate segments. We expect the group to continue benefiting from Malaysia’s growing IFM market, which had previously recorded a decent 7.
(Oct 5): RHB Research Institute initiated coverage of UEM Edgenta Bhd with a recommendation of buy.
In a filing with Bursa Malaysia, UEM Sunrise said Izzaddin has also ceased to be the company’s board tender committee chairman and member of the board development committee, as well as the ESOS Committee of the company effective Oct 1
4863 5148 1368 MYTEF BSMAF 1818
KUALA LUMPUR (Sept 13): The FBM KLCI recovered at midday break, erasing earlier losses, climbing in line with regional peers.
HLFBF UPBMF 7036 1082 BATS 4162 0096 2089 5014 CIMDF 0166 5139 1023 1368 0900 5819 MYPRY 2836
KUALA LUMPUR, Sept 11 — International Trade and Industry Minister Darell Leiking will share Malaysia’s experience in transforming the direction of production and manufacturing industries towards digitalisation, as well as learn best practices from other countries at the World Economic Forum (WEF) on Asean 2018 .
KUALA LUMPUR (Sept 7): The FBM KLCI remained under pressure at midday break today and struggled to defend its 1,800-point level.
HLFBF UPBMF 7036 1082 7113 TPGVF BATS 4162 0096 7087 5168 2089 5014 7123 TGLVY 3026 3867 1368 MYPRY 2836 GEBHF 3719 HRGHY
BROADCASTING network Astro Malaysia maintained its position despite the Communication and Multimedia Ministry saying that it is open to suggestion of other players competing with Astro to provide paid television broadcasting services in the country.
KUALA LUMPUR (Sept 5): The FBM KLCI pared some of its loss at the midday break today, but looked poised to extend its lacklustre start in September.
HLFBF APEXF PBLOF 7090 SPMXF 7036 1082 5681 BATS 4162 0162 1295 8311 6033 5199 PNADF SPMXY 3026 3301 1368 HIPEF PNAGF
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...